Diffuse large B-cell lymphoma (DLBCL) can be separated into 2 groups: nodal and extranodal disease. The aim of this study was to analyse the clinical features of skin lesions and survival outcomes of cutaneous DLBCL according to the primary tumour site. A total of 44 patients with cutaneous DLBCL were classified as primary cutaneous DLBCL, leg type or cutaneous DLBCL secondary to primary disease. Although skin lesion characteristics did not differ significantly between groups, extensive cutaneous lesions were more often observed in secondary cutaneous DLBCL compared with DLBCL, leg type. Secondary cutaneous DLBCL was more commonly associated with an advanced stage and higher International Prognostic Index score than DLBCL, leg type. DLBCL, leg type demonstrated a better survival outcome than secondary cutaneous DLBCL. The multiplicity of skin lesions and time-point of cutaneous involvement were associated with prognosis in secondary cutaneous DLBCL. Survival outcomes and prognostic factors differ depending on the primary tumour site of cutaneous DLBCL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/00015555-2139 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diffuse Large B-Cell Lymphoma Presenting Primarily as a Cutaneous Leg Lesion: A Case Report and Literature Review.
Cureus
December 2024
Hematology and Medical Oncology, East Carolina University (ECU) Health Medical Center/Brody School of Medicine, Greenville, USA.
Primary cutaneous B-cell lymphoma (PCBCL) has three subtypes, among those, the leg type variant is the rarest with the highest rates of relapse and recurrence making it an intriguing focus for researchers. Nevertheless, prior to framing a diagnosis solely based on the lesion's location, it is prudent to reconsider whether it is genuinely a primary cutaneous B-cell lymphoma (PCBCL) or if it aligns more closely with the more prevalent lymphoma variants such as diffuse large B-cell lymphoma (DLBCL) with cutaneous involvement. We are reporting a case of an 85-year-old African American lady, who presented with unilateral left leg DLBCL with cutaneous involvement.
View Article and Find Full Text PDFRecurrent primary cutaneous marginal zone lymphoma: a comparative study of initial tumours, recurrences, and outcomes in 61 patients.
Histopathology
December 2024
Pathology Department, CHU de Bordeaux, Bordeaux, France.
Article Synopsis
- - The study investigates primary cutaneous marginal zone lymphoma (PCMZL) by analyzing recurrent cases to determine whether it's a reactive process or a true lymphoma, utilizing data from the French Study Group of Cutaneous Lymphoma (GFELC).
- - Methods included assessing histology, B-cell clonality, and immunophenotype of lesions, revealing that most initial cases were localized, with differences in recurrence times based on location, and certain clonal patterns were more prominent in local recurrences.
- - The findings suggest that assessing immunoglobulin phenotype, particularly IgM and IgD, may be critical for diagnosing PCMZL, as IgM-positive cases tend to lead to more aggressive transformation and poorer prognosis, indicating different biological
Klinefelter syndrome and cutaneous localization of diffuse large B cell lymphoma: a real connection or a casual association?
Dermatol Reports
September 2024
Dermatology Unit, Toscana Centro Local Health Unit, Prato Hospital.
Article Synopsis
- Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma, representing 30-40% of cases.
- The lymphoma can spread to the skin, affecting patients in both direct and indirect ways.
- The report highlights a specific case involving skin metastasis of DLBCL in a patient who has Klinefelter Syndrome.
[Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development].
Gan To Kagaku Ryoho
July 2024
Dept. of Hematology and Oncology, University of Fukui.
Article Synopsis
- * In Japan, four ADCs are approved: gemtuzumab ozogamicin for acute myeloid leukemia, brentuximab vedotin for various types of Hodgkin's and T-cell lymphomas (showing improved progression-free survival), inotuzumab ozogamicin for B-cell acute lymphoblastic leukemia (with higher remission rates), and polatuzumab vedotin for diffuse large B-cell lymphoma (which also improves outcomes when used with standard chemotherapy).
- * Despite their
Palliating hematologic oncologic emergencies with radiation in the age of targeted systemic therapies: three illustrative cases.
Ann Palliat Med
July 2024
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.
Hematologic oncologic emergencies with an urgent indication for radiation are a relatively routine occurrence for the radiation oncologist. As patients are living longer and have multiple treatment options for their relapsed or refractory diseases, it is important that palliative treatments avoid precluding patients from or delaying next-line potentially curative treatments wherever possible. We highlight the following experiences from our clinical practice: newly diagnosed plasma cell disease causing cord compression; life threatening cutaneous lymphoma with tumors covering the majority of the body surface area; and relapsed/refractory diffuse large B-cell lymphoma (DLBCL) requiring bridging radiation to a mass impinging on the brachial plexus combined with chimeric antigen receptor (CAR)-T cell therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!